[Congressional Record Volume 165, Number 119 (Tuesday, July 16, 2019)]
[Senate]
[Pages S4830-S4831]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
Prescription Drug Costs
Mr. DURBIN. Madam President, I listened as the Republican leader came
to the floor and announced the business of the Senate for this week.
Highlighted in the business will be tax treaties--tax treaties with
Spain, Switzerland, Japan, and Luxembourg. According to the Republican
leader, these are critical to economic development in the United
States. I don't question their importance, but I will tell you that,
routinely, these are done by voice vote. We don't spend the time of the
Senate to come to the floor and talk about our relationship with
Luxembourg.
When you look at the issues that most American families expect us to
address, I would say the tax treaty with Luxembourg would be low on the
list. What might be high on the list and should be considered in the
Senate this week is the No. 1 concern of families across America--
Democrats and Republicans. The highest concern and the No. 1 issue when
asked about the economy of the United States is the cost of
prescription drugs.
The United States Senate has the authority to do something about the
cost of prescription drugs. We will not be doing it this week. We will
be dealing with a tax treaty with Luxembourg.
What kind of issues, when it comes to the cost of prescription drugs,
might be important? Let's start with one that I have started focusing
on back home.
Did you know that there are 30 million Americans who suffer from
diabetes, type 1 and type 2 diabetes? Did you know that 7.5 million
Americans use insulin every single day to stay alive? Four of them were
in my office last week from Illinois. They were between the ages of 10
and 17. Talk about amazing young people. Three young women and a young
boy talked about their lives and what had happened to them since it was
discovered that they had juvenile diabetes.
[[Page S4831]]
Their lives have been changed a lot. Each one of them is hooked up to
a CGM--I believe that is the proper term, a continuous glucose
monitor--that measures whether they need additional insulin, which is
pumped in another device on their arm. They talked about how this was a
commitment around the clock to make sure their insulin levels were
appropriate.
One little girl talked about what it meant to her family for her to
be a type 1 diabetic. This beautiful young lady started talking about
it. Then she got to the point where she said: It has changed our
family; my diabetes has changed our family.
Then she started crying.
She said: We can't do things in our family that others do. We can't
take the same vacations that my cousins take, and we can't rent that
house out on the lake because of the cost of my drugs, the cost of my
insulin.
I turned to her mother, and I said: Tell me, what does it come down
to?
Her mom said: We are lucky. We have health insurance. Our health
insurance covers prescription drugs. However, there is an $8,000
deductible. So we start each year buying the insulin for our daughter
until we have spent $8,000 out of our savings. Then the health
insurance kicks in. Usually it is about 3 months.
She is paying, or she is being charged, about $3,000 a month for
insulin.
Let's look into this for a minute as we consider why the U.S. Senate
thinks a tax treaty with Luxembourg is more important than this issue.
Let's look into the fact that insulin was discovered almost 100 years
ago in Canada, and the researchers who discovered it came to the United
States and said: We have the patent rights to this lifesaving drug for
diabetics. We never want to see anybody make a profit at the expense of
this lifesaving drug.
The Canadian researchers surrendered their patent rights to insulin
for $1--gave it up. I recall that when it came to the Salk vaccine for
polio, he did the same thing. He said that no one should ever make a
profit on a drug that eliminated polio. These two Canadian researchers
felt the same about insulin.
What happened then? Insulin was produced in the earliest stages in a
rather crude way but in an effective way to save the lives of people
with diabetes. Over the years, that process was improved. There is no
question about that.
Today there are three major pharmaceutical companies that make
insulin products for the United States--Eli Lilly of Indianapolis, IN,
is one of them; Novo Nordisk is another; Sanofi is another. I know a
little bit about the Eli Lilly product. It is called Humalog. Humalog
was introduced in the American market in 1996, an insulin product. The
charge was about $20 to $30 for a dosage--a vial, I should say, and was
used as a dosage for those with type 1 diabetes, type 2 diabetes. It
was about $21.
Here we are 20 years later, and how much is that same vial? It is
$329. Remember, this was a drug discovered almost 100 years ago.
Remember, those who could have capitalized and made a fortune off of it
surrendered their patent rights.
How did we reach the point where this drug, in 20 years, is 10 times
more than it cost when it was introduced? It is the same drug from the
same company. Why has it gone up so much in price? Because they can do
it, because these pharmaceutical companies have the power to raise
their prices, and people like that little girl in my office from
Jerseyville, IL, who broke down in tears, can't control how much that
price would be. They need this to survive.
Now you must ask yourself: What are other countries paying for
exactly the same drug made by the same American pharmaceutical company,
Eli Lilly?
We don't have to go very far to find out. All we need to go to is
Canada--Canada. The $329 Humalog vial in Canada costs $39. Why? It is
exactly the same drug and is a fraction of the cost in Canada. It is
because the Canadian Government stands up for the people of that
country and says: You cannot gouge, you cannot overprice these drugs.
You are going to be paid a reasonable amount so that you make a profit,
but you aren't going to do it at the expense of our families in Canada.
They care. They have done something about it.
We care about a tax treaty with Luxembourg. I am sorry, but as
important as that may be in that small part of the world, it is more
important for us to deal with the issue of prescription drugs and to
ask ourselves why this U.S. Senate, this empty Chamber, is not filled
with Senators of both political parties doing something about the cost
of prescription drugs.
There is one traffic cop in this Chamber. He just spoke. The
Republican leader decides what comes to the floor of the Senate. He has
decided we are not going to consider prescription drugs. Maybe he will
change his mind, but I think he will need some persuading to reach that
point.
What I am hoping is that the 30 million Americans and their families
will speak up when it comes to the cost of lifesaving insulin for
diabetes. I hope they will do the same when it comes to other drugs--so
many of them.
Senator Grassley of Iowa, a Republican, was just on the floor a few
minutes ago when we opened the session. He and I are working on a bill,
which is just a first step--and I underline, only a first step and not
the answer to the problem. But it comes down to this: You can't turn on
the television these days without seeing a drug ad. If you haven't seen
drug ads on television, you must not own a television. They are on all
the time. All of the information we are given about drugs with long
names that are hard to pronounce and remember--all of that information
is given to us over and over again so that we know much more than we
ever dreamed we would know about XARELTO. We can even spell it. We know
what different drugs are supposed to do to improve the lives of
individuals. Those ads are being thrown at us so that eventually we
have that name in our head and take it into the doctor's office and ask
for that expensive drug as opposed to a generic drug. That is running
up the cost of healthcare.
Senator Grassley and I put in a bill, and the bill is pretty basic.
With all of the things they tell you on television about the drugs, it
wasn't until just 2 weeks ago--the first time I have ever seen it--that
one of these companies disclosed the cost of the drug.
You say to yourself, maybe that is an important part of speaking to
consumers across America. Senator Grassley and I have a bill that will
require price disclosure on these pharmaceutical companies'
advertising. It is not the total answer, but I am hoping it will in
some way at least slow down, if not embarrass these companies from the
runups in cost that these drugs are going through.
That is part of the answer, but it is not the total answer by any
means. There is a long list of things we can do and should do that are
a lot more important than a tax treaty with Luxembourg, which should
pass by a voice vote without taking the time of the Senate.